MOLCURE, Inc. announced that it has received ¥800 million in funding from JAFCO Group Co., Ltd., STRIVE, Inc., SBI Investment Co., Ltd., Japan Post Capital Co., Ltd., GMO Venture Partners, Inc., Nippon Chemiphar Co., Ltd.
August 17, 2021
Share
MOLCURE, Inc. announced that it has received ¥800 million in Series C funding through third party allotment led by new investor, JAFCO Group Co., Ltd. on August 17, 2021. The transaction also included participation from new investors, STRIVE, Inc., SBI Investment Co., Ltd., Japan Post Capital Co., Ltd., returning investors, GMO Venture Partners, Inc., and Nippon Chemiphar Co., Ltd.
NIPPON CHEMIPHAR CO., LTD. is a Japan-based company centered on ethical pharmaceutical products and mainly engaged in the pharmaceutical, health and beauty related businesses. The Companyâs Pharmaceutical segment is engaged in the manufacture and sale of ethical pharmaceutical products. Other businesses include entrusted safety testing, healthcare and real estate leasing business. The Company mainly operates in Japan and Vietnam.
MOLCURE, Inc. announced that it has received ¥800 million in funding from JAFCO Group Co., Ltd., STRIVE, Inc., SBI Investment Co., Ltd., Japan Post Capital Co., Ltd., GMO Venture Partners, Inc., Nippon Chemiphar Co., Ltd.
NIPPON CHEMIPHAR CO., LTD. 